Humira

Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'

3 Stocks At An Inflection Point

FDA Accepts Coherus Biosciences' Adalimumab Biosimilar Application For Review

3 Stocks At An Inflection Point

FDA Accepts Coherus Biosciences' Adalimumab Biosimilar Application For Review

Abbott CEO Miles White Steps Down

Analysts Cut AbbVie Price Targets After Earnings Miss

Abbott CEO Miles White Steps Down

Analysts Cut AbbVie Price Targets After Earnings Miss

AbbVie's Stock Hit By Citron Tweet

Leerink Upgrades Mylan On Barrage Of Catalysts, Diversified Platforms

Humira Recent News

AbbVie Shares Double In A Year; Leerink Moves To Sidelines

Plenty Of Opportunity In AbbVie, Even After Recent Run

UBS Downgraded AbbVie Shares; Here's What Changed Analysts' View

Orphan Drugs Among 2015's Top 10 Best-Selling Medications

AbbVie's Humira Overhang Could Spell Trouble For Co.'s Future Upside

Court Date For Litigation With Amgen And Other Expectations For AbbVie

The 5 Top-Selling Drugs In The World

Recent Deals, Pipeline Updates Setting Up AbbVie For Long-Term Growth

Goldman's 7 Favorite Biotech Ideas For 2016

AbbVie Shares Trading At A Discount To Other Pharmaceuticals; Argus Reaffirms With A Buy Rating

In Barclays' View, 2016's Second Half Looks 'Noisy' For AbbVie

Biogen Optionality Looking Attractive; Bernstein Initiates At Outperform

The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers

AbbVie Falling After Q4 Report, 2016 Guidance Affirmation

Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent

Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices

What Are The Best-Selling Drugs Of 2014?